Fig. 4.

a Effectiveness over time. b Mean change in effectiveness from baseline to week 24. c Side effects over time. d Mean change in side effects from baseline to week 24. e Convenience over time. f Mean change in convenience from baseline to week 24. g Global satisfaction over time. h Mean change in global satisfaction from baseline to week 24. p values of comparison between MTX dosage groups at week 24 (ANCOVA) in a, c, e and g. **p < 0.001, comparison between scores at baseline and at week 24 (t test) for each MTX dosage group in b, d, f and h